Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) have earned an average rating of "Hold" from the six ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $11.20.

A number of research firms recently weighed in on ESPR. Morgan Stanley raised their price target on shares of Esperion Therapeutics from $7.00 to $9.00 and gave the company an "underweight" rating in a report on Wednesday, November 2nd. StockNews.com upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, November 3rd.

Insider Transactions at Esperion Therapeutics

In related news, General Counsel Benjamin Looker sold 6,347 shares of the company's stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $7.00, for a total transaction of $44,429.00. Following the transaction, the general counsel now directly owns 64,453 shares of the company's stock, valued at $451,171. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.30% of the company's stock.

Hedge Funds Weigh In On Esperion Therapeutics

Esperion Therapeutics Trading Down 0.4 %

ESPR opened at $6.69 on Thursday. The company has a fifty day simple moving average of $6.52 and a 200 day simple moving average of $6.98. The firm has a market cap of $492.95 million, a price-to-earnings ratio of -1.47 and a beta of 0.23. Esperion Therapeutics has a twelve month low of $3.28 and a twelve month high of $8.87.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.93) by $0.12. The firm had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. On average, analysts forecast that Esperion Therapeutics will post -3.65 earnings per share for the current fiscal year.

About Esperion Therapeutics

(Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Featured Stories

• Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
• AMD Is Still One Of The Best Semiconductor Stocks Out There
• Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
• Is The Bottom In For Cyber-Security Stocks?
• Union Pacific, Norfolk Southern Pull into Buying Zone
• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.